晚期慢性心力衰竭患者对levosimendan的脏反应 患者列为心脏移植预测了早期的术后功能过程
Gregor Zemljic1, Gregor Poglajen1,2, Sabina Frljak1
1Advanced Heart Failure and Transplantation Center, Department of Cardiology, University Medical Center Ljubljana, 1000 Ljubljana, Slovenia.
Journal of cardiovascular development and disease
|September 26, 2025
概括
在心脏移植候选人中,levosimendan改善了功能,反应者在移植后的早期结果更好. 这表明levosimendan响应可以预测移植后的恢复.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學.
- 移植医学 移植医学
背景情况:
- 莱沃西门丹,已知具有内效应,可以改善心力衰竭患者的功能.
- 本研究研究了levosimendan对心脏移植候选人的功能的影响及其与移植后结果的关联.
研究的目的:
- 为了研究levosimendan后的功能变化和早期移植后的结局之间的关联.
- 为了确定levosimendan响应是否可以预测心脏移植后的功能.
主要方法:
- 对99名晚期心力衰竭患者的回顾性分析,这些患者患有功能不全,正在等待心脏移植.
- 在移植前1-6个月服用Levosimendan治疗;在移植前和24小时后评估功能.
- 在24小时后增加的EGFR定义为有利的反应;移植后的功能在第1天和第7天被评估.
主要成果:
- 74% (73/99) 的患者对levosimendan (A组) 显示出良好的反应.
- 移植后A组显示功能显著改善 (ΔeGFR:+14 ± 3毫升/分钟/1.73米2),而B组显示功能恶化 (ΔeGFR:-4 ± 3毫升/分钟/1.73米2).
- 有利的levosimendan反应与移植后改善的功能独立相关 (p = 0.01).
结论:
- 在心脏移植候选人中,levosimendan后改善的功能预测了更好的早期移植后结局.
- 利沃西门达的反应可以识别可逆性功能障碍,有助于移植评估.
- 莱沃西门丹可以作为评估心脏移植候选人的脏状况的潜在工具.
相关概念视频
01:28Kidney Transplant I: Introduction
343
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
343
01:26Kidney Transplant II: Surgical Procedure
320
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
320
01:22Heart Failure Drugs: Diuretics
807
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
807
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
936
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
936
01:16Kidney Transplant III: Nursing Management
318
Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
318
01:30Heart Failure V: Medical Management
223
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
223